Brief: Stemline Therapeutics licenses from CanBas Co rights to develop & commercialize small molecule reversible inhibitor of Exportin-1
07/01/2015 21:01
Jan 7 (Reuters) - Stemline Therapeutics Inc STML.O : * In-licenses novel oral small molecule nuclear transport inhibitor targeting xpo1 * Exclusively licensed from Canbas Co rights to develop and commercialize small molecule reversible inhibitor of exportin-1 * Says Stemline expects to file an investigational new drug (ind) application in 2015 * Source text for Eikon ID:nGNXVCLIGa * Further company coverage STML.O ((Bengaluru Newsroom; +1 646 223 8780))